Selective androgen receptor modulator, S42 has anabolic and anti-catabolic effects on cultured myotubes
- PMID: 30705972
- PMCID: PMC6348734
- DOI: 10.1016/j.bbrep.2019.01.006
Selective androgen receptor modulator, S42 has anabolic and anti-catabolic effects on cultured myotubes
Abstract
We previously identified a novel selective androgen receptor modulator, S42, that does not stimulate prostate growth but has a beneficial effect on lipid metabolism. S42 also increased muscle weight of the levator ani in orchiectomized Sprague-Dawley rats. These findings prompted us to investigate whether S42 has a direct effect on cultured C2C12 myotubes. S42 significantly lowered expression levels of the skeletal muscle ubiquitin ligase (muscle atrophy-related gene), atrogin1 and Muscle RING-Finger Protein 1(MuRF1) in C2C12 myotubes, as determined by real time PCR. Phosphorylation of p70 S6 kinase (p70S6K), an essential factor for promoting protein synthesis in skeletal muscle, was significantly increased by S42 to almost the same extent as by insulin, but this was significantly prevented by treatment with rapamycin, an inhibitor of mechanistic target of rapamycin complex 1 (mTORC1). However, phosphorylation of Akt, upstream regulator of mTORC1, was not changed by S42. S42 did not increase insulin-like growth factor 1 (Igf1) mRNA levels in C2C12 myotubes. These results suggest that S42 may have an anabolic effect through activation of mTORC1-p70S6K signaling, independent of IGF-1-Akt signaling and may exert an anti-catabolic effect through inhibition of the degradation pathway in cultured C2C12 myotubes.
Keywords: C2C12; Muscle; Myotube; SARM.
Figures




Similar articles
-
A novel synthetic androgen receptor ligand, S42, works as a selective androgen receptor modulator and possesses metabolic effects with little impact on the prostate.Endocrinology. 2009 Dec;150(12):5606-16. doi: 10.1210/en.2009-0405. Epub 2009 Oct 23. Endocrinology. 2009. PMID: 19854864
-
Selective Androgen Receptor Modulator S42 Suppresses Prostate Cancer Cell Proliferation.Endocrinology. 2018 Apr 1;159(4):1774-1792. doi: 10.1210/en.2018-00099. Endocrinology. 2018. PMID: 29444261
-
Growth hormone and Insulin-like growth factor-I (IGF-I) modulate the expression of L-type amino acid transporters in the muscles of spontaneous dwarf rats and L6 and C2C12 myocytes.Growth Horm IGF Res. 2018 Oct-Dec;42-43:66-73. doi: 10.1016/j.ghir.2018.09.002. Epub 2018 Sep 23. Growth Horm IGF Res. 2018. PMID: 30273774
-
PI3 kinase regulation of skeletal muscle hypertrophy and atrophy.Curr Top Microbiol Immunol. 2010;346:267-78. doi: 10.1007/82_2010_78. Curr Top Microbiol Immunol. 2010. PMID: 20593312 Review.
-
Glucocorticoid-induced skeletal muscle atrophy.Int J Biochem Cell Biol. 2013 Oct;45(10):2163-72. doi: 10.1016/j.biocel.2013.05.036. Epub 2013 Jun 24. Int J Biochem Cell Biol. 2013. PMID: 23806868 Review.
Cited by
-
Ostarine-Induced Myogenic Differentiation in C2C12, L6, and Rat Muscles.Int J Mol Sci. 2022 Apr 15;23(8):4404. doi: 10.3390/ijms23084404. Int J Mol Sci. 2022. PMID: 35457222 Free PMC article.
-
Selective androgen receptor modulators (SARMs) have specific impacts on the mouse uterus.J Endocrinol. 2019 Sep;242(3):227-239. doi: 10.1530/JOE-19-0153. J Endocrinol. 2019. PMID: 31319382 Free PMC article.
-
Exploration of Pathogenesis and Cutting-Edge Treatment Strategies of Sarcopenia: A Narrative Review.Clin Interv Aging. 2025 May 23;20:659-684. doi: 10.2147/CIA.S517833. eCollection 2025. Clin Interv Aging. 2025. PMID: 40438271 Free PMC article. Review.
-
Advances in research on pharmacotherapy of sarcopenia.Aging Med (Milton). 2021 Aug 9;4(3):221-233. doi: 10.1002/agm2.12168. eCollection 2021 Sep. Aging Med (Milton). 2021. PMID: 34553120 Free PMC article. Review.
-
Testosterone supplementation upregulates androgen receptor expression and translational capacity during severe energy deficit.Am J Physiol Endocrinol Metab. 2020 Oct 1;319(4):E678-E688. doi: 10.1152/ajpendo.00157.2020. Epub 2020 Aug 10. Am J Physiol Endocrinol Metab. 2020. PMID: 32776828 Free PMC article.
References
-
- McCarthy J.J., Mula J., Miyazaki M., Erfani R., Garrison K., Farooqui A.B., Srikuea R., Lawson B.A., Grimes B., Keller C., Van Zant G., Campbell K.S., Esser K.A., Dupont-Versteegden E.E., Peterson C.A. Effective fiber hypertrophy in satellite cell-depleted skeletal muscle. Development. 2011;138:3657–3666. - PMC - PubMed
-
- Bodine S.C., Stitt T.N., Gonzalez M., Kline W.O., Stover G.L., Bauerlein R., Zlotchenko E., Scrimgeour A., Lawrence J.C., Glass D.J., Yancopoulos G.D. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat. Cell Biol. 2001;3:1014–1019. - PubMed
-
- Fielding R.A., Vellas B., Evans W.J., Bhasin S., Morley J.E., Newman A.B., Abellan van Kan G., Andrieu S., Bauer J., Breuille D., Cederholm T., Chandler J., De Meynard C., Donini L., Harris T., Kannt A., Keime Guibert F., Onder G., Papanicolaou D., Rolland Y., Rooks D., Sieber C., Souhami E., Verlaan S., Zamboni M. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. J. Am. Med. Dir. Assoc. 2011;12:249–256. - PMC - PubMed
-
- Metter E.J., Conwit R., Tobin J., Fozard J.L. Age-associated loss of power and strength in the upper extremities in women and men. J. Gerontol. A Biol. Sci. Med. Sci. 1997;52:B267–B276. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous